Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Jupiter Neurosciences Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Jupiter Neurosciences Inc (JUNS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors
7
Named by the company
Peer Group Market Share
100.00 %
Share of combined sales, Q2 2026
Revenue Growth Y/Y
-
Q2 2026
Net Margin
-9,380.89 %
Q2 2026

Key Findings: Jupiter Neurosciences Inc vs Its Competitors

  • Scale: Jupiter Neurosciences Inc ranks #449 of 543 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
  • Peer revenue share: Jupiter Neurosciences Inc accounted for 100.0% of combined revenue among its tracked peer group.
  • Structure: Jupiter Neurosciences Inc operates in the following segments: Premium Nutritional Supplements, Pharmaceutical Operations, Corporate and Other.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

JUNS Sales vs. its Competitors, Q2 2026

Jupiter Neurosciences Inc generated 100.00 % of the combined sales of its peer group.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/JUNS/competitors
https://api.csimarket.com/api/v1/companies/JUNS/relationships
https://api.csimarket.com/api/v1/companies/JUNS/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

Jupiter Neurosciences Inc's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity Profitable Expanding Above Industry Growth Distressed
Jupiter Neurosciences Inc - - - Yes
High-Confidence Competitors (5) 50% 75% 50% 20%
Similar-Size Competitors (10) 0% 80% 40% 33%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2026

100%market share
  • Jupiter Neurosciences Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Jupiter Neurosciences Inc and its 7 competitors.

See Jupiter Neurosciences Inc's full market share breakdown »

JUNS Stock Performance relative to its Competitors

JUNS Competitors (weighted) Percent change over the selected range

Jupiter Neurosciences Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
50%beat U.S.A. 500
High-Confidence
(1 of 2)
33.3%beat U.S.A. 500
Similar-Size
(2 of 6)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Jupiter Neurosciences Inc 69.20 % Outperformed
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (2) 40.4% 63.2%
Similar-Size Competitors (6) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Jupiter Neurosciences Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

JUNS Stock Performance relative to High-Confidence Competitors

JUNS High-Confidence Competitors (equal-weighted, 5) Percent change over the selected range

JUNS Stock Performance relative to Similar-Size Competitors

JUNS Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Jupiter Neurosciences Inc's Comment on Competition and Industry Peers

JNS operates in the pharmaceutical industry, competing with both small biotechnology firms and large pharmaceutical companies across multiple disease indications, including Parkinson's disease and rare diseases. In Parkinson's disease, existing FDA-approved treatments such as levodopa/carbidopa are available, but no recent breakthrough therapies have been introduced. In the rare diseases sector, several companies target conditions including MPS-I, offering products that compete with those of JNS. The competitive landscape is dynamic, and there is no guarantee that JNS will achieve successful competition even if its products receive approval.

Jupiter Neurosciences Inc's Competitors Named by the Company

Competitive relationships identified from Jupiter Neurosciences Inc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Sangamo Therapeutics, Inc. Company report 85% 2022 to 2026 3
Reata Pharmaceuticals Company report 85% 2022 to 2026 3
Biogen Company report 85% 2022 to 2026 3
Sanofi Genzyme Company report 85% 2022 to 2026 3
RegenexBio Company report 85% 2022 to 2026 3
Minoryx Therapeutics Company report 85% 2022 to 2026 3
Sigilon Therapeutics, Inc. Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Jupiter Neurosciences Inc's named competitors require a Commercial License.

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.

Jupiter Neurosciences Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Jupiter Neurosciences Inc Premium Nutritional Supplements 100.00 % Pharmaceutical Operations 0.00 % Corporate and Other 0.00 %

Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

Get the full CSIMarket dataset: Subscribe API Connect Your AI